Vertaling van "risk of recurrence after stopping " (Nederlands → Frans) :

Boutitie F, Pinede L, Schulman S et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participant’s data from seven trials.
Oudega R, Van Weert H, Stoffers H et al. NHG-Standaard: Diepe veneuze trombose.

Heiss G, Wallace R, Anderson GL et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
Heiss G, Wallace R, Anderson GL et al. Health risks and benefits 3 years after stoppin randomized treatment with estrogen and progestin.

A study in premenopausal women with hormone-sensitive, early-stage breast cancer showed the addition of Zometa to hormone therapy after surgery significantly reduced the risk of recurrence or death beyond benefits achieved with hormone therapy alone.
Une étude, portant sur des femmes préménopausées atteintes d’un cancer du sein au stade précoce, a montré que l’adjonction de Zometa à un traitement hormonal après intervention chirurgicale permettait une réduction significative du risque de récidive ou de décès, au-delà des bénéfices obtenus par la seule thérapie hormonale.